As methylation of RASSF1A has been reported in a variety of tumors 24, 26, RASSF1A promoter methylation has been reported to be a useful predictor for clinical outcome in lung cancer, hepatocellular carcinoma, and breast cancer 26, 27, 28. This evidence concerns the gene RASSF1 and breast carcinoma.